MRD动态预测多发性骨髓瘤进展并揭示免疫干预易感状态
该研究基于539例新诊断多发性骨髓瘤患者的3,610次MRD评估,定义了五种MRD动态亚组,其生存差异显著且优于R-ISS。多组学分析揭示MRD抵抗伴随基因组演化、转录适应和促炎肿瘤免疫微环境,小鼠模型显示在MRD抵抗期而非复发期使用抗BCMA CAR-T可延长生存。
要点
- 基于≥3次MRD评估的动态分组可区分生存差异显著的五类患者。
- 晚期持续MRD反应与早期持续反应预后同样良好,而波动或抵抗者生存差。
- MRD抵抗期存在免疫微环境改变,此阶段CAR-T干预可能优于复发时治疗。
核心结论
- MRD动态是进展的最强预测因素,有助于在复发前调整治疗以预防肿瘤和免疫改变。
研究设计与样本
- 在GEM2012MENOS65/GEM2014MAIN和GEM2017FIT试验的539例新诊断MM患者中,用二代流式和Connector计算MRD动态。
- 在MIcγ1huCRBN小鼠中比较持续MRD与复发时使用抗BCMA CAR-T的生存影响。
- 对匹配的诊断和MRD样本进行分子与免疫分析,并在249例常规实践患者中验证。
主要发现
- 基于3,610次MRD评估识别出五个生存不同的亚组,MRD动态预测优于移植资格和R-ISS。
- 晚期持续MRD反应者结局优异,与早期持续反应者相似;波动和原发/再燃抵抗者生存差。
- MRD抵抗患者和小鼠模型显示基因组演化、转录适应及促炎肿瘤免疫微环境。
- 疾病进展中内源性T细胞克隆性增加和耗竭,提示免疫干预时机。
- 小鼠中MRD抵抗期输注抗BCMA CAR-T较复发时输注延长生存。
关键数值与推荐
- MRD动态基于≥3次评估计算,共3,610次评估,识别五组生存差异显著的患者。
- MRD动态预测预后优于移植资格和R-ISS,并在249例常规实践患者中验证。
临床怎么用
- 可利用≥3次MRD评估的动态模式对MM患者进行风险分层。
- MRD抵抗状态可能是免疫治疗干预的窗口,但需进一步临床验证。
局限性
- 小鼠模型结果需在人体临床试验中验证MRD拦截策略。
- 研究基于特定临床试验队列,常规实践验证样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical significance of one or two measurable residual disease (MRD) assessments is established in multiple myeloma (MM). However, how to stratify patients according to ≥3 MRD assessments remains unknown. The traits of MRD resistance and if treatment of persistent MRD vs relapse could improve outcomes also remains unknown. MRD dynamics were computed using next-generation flow cytometry and Connector in 539 newly-diagnosed MM patients with ≥3 assessments in the GEM2012MENOS65/GEM2014MAIN and GEM2017FIT trials. Molecular and immune profiling were performed in matched diagnostic and MRD samples. The survival impact of treating persistent MRD vs relapse was investigated with anti-BCMA CAR T cells in MIcγ1huCRBN mice. Computed MRD dynamics based on 3,610 MRD assessments identified five subgroups with different survival. Patients with late-sustained MRD response had excellent outcomes, similar to those with early-sustained MRD response. Patients with volatile results and those with primarily and resurgent MRD resistance had dismal survival. MRD dynamics outperformed transplant-eligibility and the R-ISS. These results were validated in 249 MM patients treated in routine practice. Multiomics characterization of MRD dynamics in patients and mouse models of MRD resistance revealed genomic evolution, transcriptional adaption and a pro-inflammatory tumor-immune microenvironment. Increasing clonality and exhaustion of endogenous T cells throughout disease progression urged investigating if MRD interception with anti-BCMA CAR-T cells could improve outcomes. Infusion at MRD resistance prolonged mouse survival compared to identical treatment at relapse. Altogether, MRD dynamics is the strongest predictor of progression and may help tailoring treatment to prevent additional tumor and immune alterations prior to relapse.
引用
- Gonzalez C, Guerrero C, Larrayoz M, et al. MRD dynamics predicts progression and reveals a vulnerable state for immunotherapy interception in multiple myeloma. Blood. 2026. PMID: 42498680. doi:10.1182/blood.2026033878
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。